Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Claes Ginman"'
Autor:
Björn Tavelin, Mihajl Seke, David Norman, Lars Franzén, Anders Widmark, Per Fransson, Lars Beckman, Björn Zackrisson, Morten Høyer, Per Nilsson, Camilla Thellenberg-Karlsson, Elisabeth Kjellén, Jon Kindblom, Adalsteinn Gunnlaugsson, Bengt Johansson, Kirsten Björnlinger, Claes Ginman, Magnus Lagerlund, Måns Agrup
Publikováno v:
Fransson, P, Nilsson, P, Gunnlaugsson, A, Beckman, L, Tavelin, B, Norman, D, Thellenberg-Karlsson, C, Hoyer, M, Lagerlund, M, Kindblom, J, Ginman, C, Johansson, B, Björnlinger, K, Seke, M, Agrup, M, Zackrisson, B, Kjellén, E, Franzén, L & Widmark, A 2021, ' Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC) : patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial ', The Lancet Oncology, vol. 22, no. 2, pp. 235-245 . https://doi.org/10.1016/S1470-2045(20)30581-7
Background: The HYPO-RT-PC trial compared conventionally fractionated radiotherapy with ultra-hypofractionated radiotherapy in patients with localised prostate cancer. Ultra-hypofractionation was non-inferior to conventional fractionation regarding 5
Autor:
Miikka Lehtonen, Jorma Sormunen, Tiina Luukkaala, Timo Marttila, Ray McDermott, Timo Joensuu, Ilari Lehtinen, Claes Ginman, Pirkko-Liisa Kellokumpu-Lehtinen
Introduction: Treatment with 2-weekly docetaxel 50 mg/m2 was shown to improve overall survival and was better tolerated than the standard 75 mg/m2 3-weekly regimen in men with metastatic castration-resistant prostate cancer (mCRPC) in the original ra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::122cbeb4f20ed8b0403fb5ff04a84700
https://trepo.tuni.fi/handle/10024/141440
https://trepo.tuni.fi/handle/10024/141440
Autor:
Miikka, Lehtonen, Jorma, Sormunen, Marie, Hjälm-Eriksson, Camilla, Thellenberg-Karlsson, Teppo, Huttunen, Claes, Ginman, Pirkko-Liisa, Kellokumpu-Lehtinen
Publikováno v:
Anticancer research. 42(1)
The goal of this study was to investigate whether health-related quality of life (HRQoL) was affected in patients with high- or intermediate-risk localized prostate cancer treated with docetaxel following radiation therapy (RT).A total of 376 patient
Autor:
Pirkko-Liisa Kellokumpu-Lehtinen, Marie Hjälm-Eriksson, Claes Ginman, Teppo Huttunen, Ann-Fofie Fransson, Lennat Åström, Lars Franzén, Camilla Thellenberg-Karlsson, Markku J Leskinen, Mihalj Zeke
Publikováno v:
European Urology. 78:e241-e242
Autor:
Camilla Thellenberg-Karlsson, Lars Beckman, Adalsteinn Gunnlaugsson, Lars Franzén, Kirsten Björnlinger, Elisabeth Kjellén, Claes Ginman, Per Fransson, Harald Anderson, Magnus Lagerlund, Mihajl Seke, Björn Tavelin, Måns Agrup, Anders Widmark, Bengt Johansson, Morten Høyer, Jon Kindblom, David Norman, Per Nilsson, Björn Zackrisson
Publikováno v:
Widmark, A, Gunnlaugsson, A, Beckman, L, Thellenberg-Karlsson, C, Hoyer, M, Lagerlund, M, Kindblom, J, Ginman, C, Johansson, B, Björnlinger, K, Seke, M, Agrup, M, Fransson, P, Tavelin, B, Norman, D, Zackrisson, B, Anderson, H, Kjellén, E, Franzén, L & Nilsson, P 2019, ' Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer : 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial ', The Lancet, vol. 394, no. 10196, pp. 385-395 . https://doi.org/10.1016/S0140-6736(19)31131-6
International Brazilian Journal of Urology : official journal of the Brazilian Society of Urology
International Brazilian Journal of Urology : official journal of the Brazilian Society of Urology
Summary Background Hypofractionated radiotherapy for prostate cancer has gained increased attention due to its proposed high radiation-fraction sensitivity. Recent reports from studies comparing moderately hypofractionated and conventionally fraction
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::38f2576a4a1ca40683b1abdff06eb0d1
https://pure.au.dk/portal/da/publications/ultrahypofractionated-versus-conventionally-fractionated-radiotherapy-for-prostate-cancer(4232e2f3-4a07-4b9e-b725-107553d11dbd).html
https://pure.au.dk/portal/da/publications/ultrahypofractionated-versus-conventionally-fractionated-radiotherapy-for-prostate-cancer(4232e2f3-4a07-4b9e-b725-107553d11dbd).html
Autor:
Silvia Johansson, Claes Ginman, Anna Ottenblad, Marina Forslund, Birgitta Johansson, Peter Nygren
Publikováno v:
Supportive Care in Cancer
Purpose Radiotherapy to the prostate gland and pelvic lymph nodes may cause acute and late bowel symptoms and diminish quality of life. The aim was to study the effects of a nutrition intervention on bowel symptoms and health-related quality of life,
Autor:
Lars Franzén, Lennart Åström, Teppo Huttunen, Marie Hjälm-Eriksson, Camilla Thellenberg-Karlsson, Mihalj Zeke, Pirkko-Liisa Kellokumpu-Lehtinen, Claes Ginman, Markku J Leskinen, Ann-Sofie Fransson
Publikováno v:
European urology. 76(6)
Background Docetaxel combined with androgen deprivation therapy (ADT) has improved patient survival for advanced prostate cancer (PCa). Objective This randomised trial aimed to evaluate whether six courses of docetaxel improved biochemical disease–
Autor:
Ann-Sofie Fransson, Pirkko-Liisa Kellokumpu-Lehtinen, Lars Franzén, Claes Ginman, Teppo Huttunen, Markku J Leskinen, Camilla Thellenberg-Karlsson, Marie Hjälm-Eriksson, Lennart Åström
Publikováno v:
Journal of Clinical Oncology. 38:313-313
313 Background: Six docetaxel cycles did not improve PSA relapse free survival as an adjuvant treatment after radical RT (Kellokumpu-Lehtinen EURURO-8532). Here we report SPCG-13 trials QoL results. Methods: A total of 376 PC patients (T2 with Gleaso
Autor:
Camilla Thellenberg-Karlsson, Morten Høyer, Anders Widmark, Per Fransson, Mihalj Seke, Elisabeth Kjellén, Jon Kindblom, Lars Franzén, Magnus Lagerlund, Bengt Johansson, Adalsteinn Gunnlaugsson, Per Nilsson, Kirsten Björnlinger, Claes Ginman, Lars Beckman
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 96:938-939
Extreme Hypofractionation versus Conventionally Fractionated Radiotherapy for Intermediate Risk Prostate Cancer : Early Toxicity Results from the Scandinavian Randomized Phase III Trial "HYPO-RT-PC"
Autor:
Teppo Huttunen, Camilla Thellenberg-Karlsson, Widmark Anders, Marie Hjälm-Eriksson, Lennart Åström, Sten Nilsson, Timo Marttila, Pirkko-Liisa Kellokumpu-Lehtinen, Claes Ginman
Publikováno v:
Journal of Clinical Oncology. 36:5000-5000
5000Background: Docetaxel combined with androgen deprivation therapy (ADT) has improved survival in advanced prostate cancer (PCa). This randomized trial evaluates if six courses of docetaxel impro...